Numerous clinical trials evaluate gefitinib across multiple oncology settings, focusing primarily on non-small cell lung cancer (NSCLC) subtypes—including EGFR mutation-positive advanced NSCLC and adenocarcinoma—as well as metastatic colorectal cancer. Spanning Phase 1 through Phase 3, these studies investigate gefitinib alone and in combination strategies alongside other VEGFR or tyrosine kinase inhibitors. Sponsored by academic institutions and pharmaceutical companies such as AstraZeneca, Daiichi Sankyo, Eli Lilly, and Sun Yat-sen University, these investigations encompass completed, active not recruiting, terminated, withdrawn, and unknown recruitment statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07458919 | NOT_YET_RECRUITING | Lung Cancer |
Fuzhou General Hospital |
2026-03-30 | EARLY_PHASE1 |
| NCT07477457 | RECRUITING | Osteosarcoma; Metastasis |
Memorial Sloan Kettering Cancer Center |
2026-03-11 | PHASE2 |
| NCT03040973 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors Which Are cMET-dependent |
Novartis Pharmaceuticals |
2017-08-23 | PHASE2 |
| NCT03333343 | ACTIVE_NOT_RECRUITING | EGFR-mutant Non-small Cell Lung Cancer |
Novartis Pharmaceuticals |
2018-01-29 | PHASE1 |
| NCT03122717 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Dana-Farber Cancer Institute |
2017-05-09 | PHASE1; PHASE2 |
| NCT06071013 | RECRUITING | Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation |
China Medical University Hospital |
2024-02-23 | PHASE1; PHASE2 |
| NCT03203590 | UNKNOWN | 2-year Disease-Free Survival |
Sun Yat-sen University |
2017-09 | PHASE3 |
| NCT03944772 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2019-06-25 | PHASE2 |
| NCT02347839 | WITHDRAWN | Lung Cancer |
Sun Yat-sen University |
2016-01-01 | PHASE2 |
| NCT04143607 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic NSCLC |
Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
2019-07-23 | PHASE3 |
| NCT02824458 | UNKNOWN | EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors |
Sun Yat-sen University |
2016-06 | PHASE3 |
| NCT03866499 | UNKNOWN | NSCLC |
Beta Pharma Shanghai |
2021-04-30 | PHASE3 |
| NCT03239015 | UNKNOWN | Rare Tumor; Refractory Tumor |
Baodong Qin |
2017-01-01 | PHASE2 |
| NCT04642547 | COMPLETED | Hepatocellular Carcinoma; Molecular Targeted Therapy |
RenJi Hospital |
2020-12-02 | |
| NCT03381430 | UNKNOWN | Lung Cancer |
Qilu Pharmaceutical Co., Ltd. |
2018-06 | |
| NCT03381066 | UNKNOWN | Completely Resected NSCLC With Common EGFR Mutations |
Yonsei University |
2018-04-10 | PHASE3 |
| NCT02856893 | COMPLETED | NSCLC |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-10-10 | PHASE2 |
| NCT04248829 | COMPLETED | Non-Small Cell Lung Cancer |
Yuhan Corporation |
2020-02-13 | PHASE3 |
| NCT03653546 | COMPLETED | Non-small Cell Lung Cancer; EGFR Gene Mutation; Brain Metastases |
Alpha Biopharma (Jiangsu) Co., Ltd. |
2018-10-29 | PHASE2; PHASE3 |
| NCT01951469 | UNKNOWN | Non-small Cell Lung Cancer; Brain Metastases; EGFR Mutation |
Sun Yat-sen University |
2016-01 | PHASE3 |
| NCT04358562 | UNKNOWN | Non-small Cell Lung Cancer; EGFR Gene Mutation |
Second Affiliated Hospital of Nanchang University |
2020-05-01 | PHASE2 |
| NCT04874844 | UNKNOWN | NSCLC |
Beijing Dongfang Biotech Co., Ltd. |
2021-07-30 | PHASE2; PHASE3 |
| NCT03856697 | UNKNOWN | Advanced Non-small Cell Lung Cancer |
Hangzhou ACEA Pharmaceutical Research Co., Ltd. |
2019-03 | PHASE3 |
| NCT04239833 | UNKNOWN | Non-Small Cell Lung Cancer |
Nanjing Sanhome Pharmaceutical, Co., Ltd. |
2020-01-31 | PHASE3 |
| NCT04425187 | UNKNOWN | PFS |
Fudan University |
2020-06-08 | PHASE2 |
| NCT03292133 | TERMINATED | Lung Cancer |
Massachusetts General Hospital |
2017-10-31 | PHASE2 |
| NCT03264794 | UNKNOWN | Non-small Cell Lung Cancer |
Jiangsu Famous Medical Technology Co., Ltd. |
2017-08 | PHASE4 |
| NCT03170180 | COMPLETED | Stomach Neoplasms |
Samsung Medical Center |
2017-03-01 | PHASE2 |
| NCT03758287 | COMPLETED | Non-small Cell Lung Cancer |
Sunshine Lake Pharma Co., Ltd. |
2016-11 | PHASE1; PHASE2 |
| NCT03787992 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer |
Allist Pharmaceuticals, Inc. |
2019-05-30 | PHASE3 |
| NCT03720873 | UNKNOWN | EGFR Gene Mutation |
Fujian Cancer Hospital |
2018-10 | PHASE2 |
| NCT02088112 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
MedImmune LLC |
2014-03-24 | PHASE1 |
| NCT04390984 | UNKNOWN | NSCLC |
Jiangsu HengRui Medicine Co., Ltd. |
2020-05-26 | PHASE1 |
| NCT03849768 | UNKNOWN | Non Small Cell Lung Cancer |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2019-02-01 | PHASE3 |
| NCT04028778 | UNKNOWN | Lung Cancer, Nonsmall Cell |
Sun Yat-sen University |
2019-04-10 | PHASE3 |
| NCT00317772 | COMPLETED | Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Cancer |
M.D. Anderson Cancer Center |
2004-09-02 | PHASE1; PHASE2 |
| NCT03457337 | UNKNOWN | Advanced NSCLC With EGFR Mutation |
Henan Cancer Hospital |
2018-03-28 | PHASE2 |
| NCT03267654 | UNKNOWN | Non-small-cell Lung Cancer |
Qilu Pharmaceutical Co., Ltd. |
2017-10-12 | PHASE2 |
| NCT02893332 | TERMINATED | Stage IV EGFR Mutated Non-Small Cell Lung Cancer |
Sichuan Provincial People's Hospital |
2016-01-15 | PHASE3 |
| NCT03529084 | WITHDRAWN | Carcinoma, Non-small Cell Lung |
Novartis Pharmaceuticals |
2018-07-24 | PHASE3 |
| NCT03656393 | UNKNOWN | NSCLC; EGFR |
Shenzhen People's Hospital |
2018-08-31 | PHASE3 |
| NCT02447419 | COMPLETED | Solid Tumor |
Samsung Medical Center |
2014-12-03 | PHASE2 |
| NCT03599518 | TERMINATED | Non Small Cell Lung Cancer |
Daiichi Sankyo Co., Ltd. |
2018-09-21 | PHASE1 |
| NCT02416739 | UNKNOWN | Non-Small-Cell Lung Carcinoma |
Il Yeong Park, Ph.D. |
2015-03 | PHASE2; PHASE3 |
| NCT02882984 | UNKNOWN | Stage IV EGFR Mutated NSCL With Brain Metastases |
Sichuan Provincial People's Hospital |
2015-03 | PHASE3 |
| NCT03374280 | UNKNOWN | Non Small Cell Lung Cancer |
Guangzhou Medical University |
2016-12-01 | PHASE2 |
| NCT03766490 | UNKNOWN | Non-Small-Cell Lung |
The First Affiliated Hospital of Soochow University |
2019-03-30 | |
| NCT02836847 | UNKNOWN | Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer |
Shanghai Jiao Tong University School of Medicine |
2016-07 | PHASE2 |
| NCT03341494 | UNKNOWN | NSCLC Stage IV; Chemotherapy Effect |
Fujian Cancer Hospital |
2017-04-01 | PHASE2 |
| NCT00282100 | UNKNOWN | Liver Cancer |
Tan Tock Seng Hospital |
2005-12 | PHASE2 |
| NCT07271446 | COMPLETED | Non-small Cell Lung Cancer |
Precision Biotech Taiwan Corp. |
2018-09-01 | PHASE1 |
| NCT02976116 | COMPLETED | NSCLC |
Hutchison Medipharma Limited |
2016-12 | PHASE2 |
| NCT03486496 | UNKNOWN | Lung Adenocarcinoma; EGFR Mutation |
Fujian Cancer Hospital |
2018-06-05 | PHASE2 |
| NCT03050411 | UNKNOWN | Nonsmall Cell Lung Cancer |
Peking University Third Hospital |
2016-05 | PHASE1 |
| NCT02929693 | UNKNOWN | Cancer |
Shanghai University of Traditional Chinese Medicine |
2016-10 | PHASE3 |
| NCT03123484 | UNKNOWN | Non Small Cell Lung Cancer |
China Medical University, China |
2017-04 | PHASE2 |
| NCT02411448 | ACTIVE_NOT_RECRUITING | Metastatic Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2015-05-06 | PHASE3 |
| NCT03602027 | UNKNOWN | Non-squamous Non-small Cell Lung Cancer |
Second Affiliated Hospital of Nanchang University |
2018-08-01 | |
| NCT02930954 | UNKNOWN | Non-small-cell Lung Cancer |
Caicun Zhou |
2016-11 | PHASE2 |
| NCT03599518 | Terminated | Non Small Cell Lung Cancer |
Daiichi Sankyo Co. Ltd.|Daiichi Sankyo |
2018-09-21 | Phase 1 |
| NCT03399669 | UNKNOWN | Non-small Cell Lung Cancer |
Samsung Medical Center |
2015-02-17 | PHASE2 |
| NCT01556191 | COMPLETED | Stage IV Lung Cancer |
Intergroupe Francophone de Cancerologie Thoracique |
2012-05-15 | PHASE2 |
| NCT02951637 | UNKNOWN | Lung Adenocarcinoma |
Shanghai Chest Hospital |
2016-12 | PHASE2 |
| NCT02025114 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) |
National Taiwan University Hospital |
2014-09 | PHASE1; PHASE2 |
| NCT02804776 | COMPLETED | Non-small Cell Lung Cancer |
National Cancer Centre, Singapore |
2015-01-27 | PHASE2 |
| NCT02151721 | UNKNOWN | Non-Small-Cell Lung Carcinoma |
Kanazawa University |
2014-06-01 | PHASE1 |
| NCT02374645 | COMPLETED | Non-Small Cell Lung Cancer |
Hutchison Medipharma Limited |
2015-04 | PHASE1 |
| NCT02518802 | UNKNOWN | Lung Neoplasms |
Tang-Du Hospital |
2015-01 | PHASE3 |
| NCT02588261 | TERMINATED | Non-small Cell Lung Cancer (NSCLC) |
Astellas Pharma Global Development, Inc. |
2016-02-11 | PHASE3 |
| NCT01982955 | COMPLETED | Non-small Cell Lung Cancer |
Merck KGaA, Darmstadt, Germany |
2013-12-23 | PHASE1; PHASE2 |
| NCT02282267 | UNKNOWN | Lung Adenocarcinoma |
Peking University Cancer Hospital & Institute |
2014-10 | |
| NCT01864681 | COMPLETED | NSCLC; EGFR Gene Amplification; Advanced Cancer; Stage IIIB NSCLC; Stage IV NSCLC |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2013-05 | PHASE2 |
| NCT01965275 | UNKNOWN | Self Efficacy; Drug Toxicity |
Anhui Medical University |
2013-10 | PHASE2 |
| NCT02338011 | UNKNOWN | Non-Small Cell Lung Cancer; Brain Metastases; EGFR Gene Mutation |
Shanghai Chest Hospital |
2014-11 | PHASE2; PHASE3 |
| NCT02299765 | TERMINATED | Non-small Cell Lung Cancer Metastatic; EGFR Activating Mutation |
Sichuan University |
2014-12 | PHASE4 |
| NCT03292133 | Active not recruiting | Lung Cancer |
Massachusetts General Hospital|Novartis |
2017-10-31 | Phase 2 |
| NCT02296125 | COMPLETED | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer |
AstraZeneca |
2014-12-03 | PHASE3 |
| NCT02387086 | UNKNOWN | NSCLC |
Bai Jun |
2015-05 | PHASE2; PHASE3 |
| NCT02013089 | UNKNOWN | Gastrointestinal Cancers |
Sun Yat-sen University |
2013-12 | |
| NCT03122717 | Active not recruiting | Non-Small Cell Lung Cancer |
Dana-Farber Cancer Institute|AstraZeneca |
2017-05-09 | Phase 1|Phase 2 |
| NCT01933347 | COMPLETED | Non Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2014-04-07 | PHASE2 |
| NCT02326285 | TERMINATED | Non-squamous Non-small Cell Lung Cancer Stage II; Non-squamous Non-small Cell Lung Cancer Stage IIIA; Non-squamous Non-small Cell Lung Cancer Stage IIIB; Activating EGFR Mutation; NSCLC |
AIO-Studien-gGmbH |
2015-11 | PHASE2; PHASE3 |
| NCT01405079 | UNKNOWN | Non-small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2011-09-19 | PHASE3 |
| NCT02025218 | TERMINATED | Lung Cancer |
Amsterdam UMC, location VUmc |
2014-01 | PHASE2 |
| NCT02889692 | COMPLETED | Cancer |
Shanghai University of Traditional Chinese Medicine |
2013-03 | PHASE3 |
| NCT03050177 | COMPLETED | Healthy |
Hunan Kelun Pharmaceutical Co., Ltd. |
2016-09-01 | PHASE1 |
| NCT02031601 | UNKNOWN | Non-Small-Cell Lung Cancer |
Qilu Hospital of Shandong University |
2014-01 | PHASE4 |
| NCT01749072 | UNKNOWN | Non-small Cell Lung Cancer; Effects of Chemotherapy |
Peking Union Medical College Hospital |
2012-12 | PHASE2 |
| NCT02039674 | COMPLETED | Non-small Cell Lung Carcinoma |
Merck Sharp & Dohme LLC |
2014-02-21 | PHASE1; PHASE2 |
| NCT03050164 | COMPLETED | Bioequivalence Study |
Hunan Kelun Pharmaceutical Co., Ltd. |
2016-09-08 | PHASE1 |
| NCT00986284 | SUSPENDED | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2009-09 | PHASE2 |
| NCT02932345 | Terminated | EGFR Mutation Positive Advanced Non-small-cell Lung Cancer |
AstraZeneca |
2016-10-31 | -- |
| NCT00509002 | COMPLETED | Salivary Gland Cancer |
M.D. Anderson Cancer Center |
2004-05 | PHASE2 |
| NCT02321293 | UNKNOWN | Lung Cancer |
Lady Davis Institute |
2015-08 | PHASE1 |
| NCT01774721 | COMPLETED | Non-small Cell Lung Cancer With EGFR-Activating Mutations |
Pfizer |
2013-05-09 | PHASE3 |
| NCT01513174 | COMPLETED | Non Small Cell Lung Cancer |
Spanish Lung Cancer Group |
2011-08 | PHASE1; PHASE2 |
| NCT02179671 | COMPLETED | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) |
AstraZeneca |
2014-07-25 | PHASE2 |
| NCT01610336 | COMPLETED | Non-small Cell Lung Cancer |
Novartis Pharmaceuticals |
2012-04-05 | PHASE2 |
| NCT02824458 | Unknown status | EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors |
Sun Yat-sen University |
2016-06 | Phase 3 |
| NCT01955421 | UNKNOWN | Advanced Stage Non Small Cell Lung Cancer |
Sun Yat-sen University |
2013-07 | PHASE2 |
| NCT01466660 | COMPLETED | Lung Neoplasms |
Boehringer Ingelheim |
2011-12-13 | PHASE2 |
| NCT01405846 | TERMINATED | Lung Cancer; Head and Neck Cancer |
Papworth Hospital NHS Foundation Trust |
2011-12 | PHASE2 |
| NCT02040064 | COMPLETED | Non Small Cell Lung Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2014-01 | PHASE1 |
| NCT01570296 | COMPLETED | Non-Small Cell Lung Cancer; Solid Tumors |
National Cancer Centre, Singapore |
2011-10-03 | PHASE1 |
| NCT01720901 | SUSPENDED | Non-small Cell Lung Cancer |
Betta Pharmaceuticals Co., Ltd. |
2013-02 | PHASE4 |
| NCT01871480 | TERMINATED | Non-Small Cell Lung Cancer |
Kunming Medical University |
2013-05 | PHASE2 |
| NCT01784549 | UNKNOWN | Non Small Cell Lung Cancer |
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
2012-07 | PHASE2 |
| NCT01833572 | COMPLETED | Non-small-cell Lung Cancer |
Fudan University |
2013-05 | PHASE2 |
| NCT02484755 | UNKNOWN | Cushing's Disease; Corticotrophin Adenoma |
Huashan Hospital |
2015-06 | PHASE2 |
| NCT00086957 | COMPLETED | Breast Cancer |
City of Hope Medical Center |
2004-01 | PHASE1; PHASE2 |
| NCT01024413 | COMPLETED | Thoracic Neoplasms |
Chinese Society of Lung Cancer |
2009-07 | PHASE3 |
| NCT02319577 | UNKNOWN | Non Small Cell Lung Cancer |
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
2012-03 | PHASE2 |
| NCT00357734 | COMPLETED | Lung Cancer; Breast Cancer |
AstraZeneca |
2005-01 | PHASE3 |
| NCT01732276 | UNKNOWN | Breast Cancer |
Jiangmen Central Hospital |
2013-01 | PHASE2 |
| NCT01469000 | COMPLETED | Carcinoma, Non Small Cell Lung |
Eli Lilly and Company |
2012-02 | PHASE2 |
| NCT01928160 | WITHDRAWN | Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2014-06 | PHASE2 |
| NCT01404260 | COMPLETED | Non-small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2011-06 | PHASE3 |
| NCT01932229 | UNKNOWN | NSCLC |
Sheba Medical Center |
2013-02 | PHASE2 |
| NCT02148380 | COMPLETED | Non-Small-Cell Lung Cancer |
Baohui Han |
2014-05 | |
| NCT02747953 | COMPLETED | Non-small Cell Lung Cancer |
Samsung Medical Center |
2011-07 | PHASE2 |
| NCT00809237 | UNKNOWN | Non-small Cell Lung Cancer |
National University Hospital, Singapore |
2008-11 | PHASE1; PHASE2 |
| NCT00993499 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2009-10 | PHASE1 |
| NCT01502202 | UNKNOWN | Non Small Cell Lung Cancer; Adenocarcinoma |
National Cancer Center, Korea |
2012-03 | PHASE2 |
| NCT01602289 | COMPLETED | Solid Tumors; Lymphoma; Carcinoma, Non-Small-Cell Lung |
Eli Lilly and Company |
2012-06 | PHASE1 |
| NCT01530334 | COMPLETED | Lung Cancer |
AstraZeneca |
2012-07 | PHASE2 |
| NCT01498562 | COMPLETED | Non Small Cell Lung Cancer (NSCLC) |
Yonsei University |
2011-12 | PHASE2 |
| NCT01783834 | COMPLETED | Previous Treated Metastatic Non-small Cell Lung Cancer |
Gachon University Gil Medical Center |
2008-02 | PHASE2 |
| NCT01544179 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2012-03-15 | PHASE3 |
| NCT01776684 | UNKNOWN | EGFR Mutation Positive Non-small Cell Lung Cancer |
Samsung Medical Center |
2012-06 | |
| NCT01769066 | COMPLETED | NSCLC |
Fudan University |
2009-12 | PHASE2; PHASE3 |
| NCT01755923 | UNKNOWN | Non-small Cell Lung Cancer |
Peking Union Medical College Hospital |
2012-12 | PHASE2 |
| NCT01027676 | UNKNOWN | Non-Small-Cell Lung Carcinoma |
National Cancer Center, Korea |
2010-06 | PHASE1; PHASE2 |
| NCT00711594 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2008-04 | PHASE2 |
| NCT01085136 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2010-02 | PHASE3 |
| NCT00656136 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2008-04 | PHASE3 |
| NCT01039948 | COMPLETED | Carcinoma, Non-Small Cell-Lung; Lung Neoplasms; Lung Cancer; Respiratory Tract Neoplasms |
AVEO Pharmaceuticals, Inc. |
2009-12 | PHASE1; PHASE2 |
| NCT01147211 | UNKNOWN | Non Small Cell Lung Cancer |
National Taiwan University Hospital |
2010-09 | PHASE1 |
| NCT01510990 | UNKNOWN | Non-small Cell Lung Cancer |
Asan Medical Center |
2012-04 | PHASE2 |
| NCT01579630 | UNKNOWN | NSCLC |
Taipei Veterans General Hospital, Taiwan |
2011-03 | PHASE2; PHASE3 |
| NCT03157310 | COMPLETED | Overal Survival, Non-small Cell Lung Cancer |
Qilu Hospital of Shandong University |
2009-05-01 | |
| NCT01158170 | UNKNOWN | Non-small Cell Lung Cancer |
Zhejiang Cancer Hospital |
2010-06 | PHASE3 |
| NCT01310855 | TERMINATED | Glioblastoma |
University College, London |
2011-05 | PHASE2 |
| NCT00077025 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE2 |
| NCT01017874 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2009-11 | PHASE3 |
| NCT00493025 | TERMINATED | Esophageal Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2005-04 | PHASE2 |
| NCT00126555 | COMPLETED | Recurrent Skin Cancer; Squamous Cell Carcinoma of the Skin |
National Cancer Institute (NCI) |
2005-03 | PHASE2 |
| NCT01090011 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2010-03 | PHASE1 |
| NCT00372515 | COMPLETED | Non-Small Cell Lung Cancer |
David M. Jackman, MD |
2006-06 | PHASE1 |
| NCT01291823 | UNKNOWN | Esophageal Cancer |
Zhejiang Cancer Hospital |
2010-12 | PHASE2 |
| NCT00891579 | COMPLETED | Non Small Cell Lung Cancer |
Chinese Society of Lung Cancer |
2009-02 | PHASE2 |
| NCT01363557 | TERMINATED | EGFR-mutated Lung Adenocarcinoma; Brain Metastasis |
Assistance Publique - Hôpitaux de Paris |
2012-03 | |
| NCT01312337 | UNKNOWN | Nonsmall Cell Lung Cancer |
Samsung Medical Center |
2010-09 | PHASE2 |
| NCT01203917 | COMPLETED | Caucasian Patients With EGFR Mutation Positive Advanced NSCLC |
AstraZeneca |
2010-09 | PHASE4 |
| NCT01391260 | UNKNOWN | Non-small Cell Lung Cancer |
ZhuGuangYing |
2011-07 | PHASE2 |
| NCT00057941 | COMPLETED | Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2003-09 | PHASE2 |
| NCT01243398 | COMPLETED | Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer |
University of Oxford |
2009-03 | PHASE3 |
| NCT01196234 | COMPLETED | Non Small Cell Lung Cancer |
Asan Medical Center |
2009-12 | PHASE2 |
| NCT00352079 | TERMINATED | Bladder Cancer |
NCIC Clinical Trials Group |
2007-01-04 | PHASE3 |
| NCT01017679 | COMPLETED | Non-small Cell Lung Cancer |
Sun Yat-sen University |
2009-05 | PHASE2 |
| NCT01189435 | TERMINATED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2010-08 | PHASE2 |
| NCT01192243 | UNKNOWN | Toxicity; Non-small Cell Lung Cancer |
Fudan University |
2009-12 | PHASE2 |
| NCT01192230 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Fudan University |
2009-06 | PHASE2 |
| NCT01485809 | COMPLETED | Squamous Cell Carcinoma of Bronchus |
Seoul Veterans Hospital |
2011-10 | PHASE2 |
| NCT00132158 | COMPLETED | Glioblastoma; Rhabdomyosarcomas; Neuroblastoma; Osteosarcoma |
St. Jude Children's Research Hospital |
2005-09 | PHASE1 |
| NCT00570401 | COMPLETED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2006-06 | PHASE2 |
| NCT00824746 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Chonnam National University Hospital |
2009-01 | PHASE2 |
| NCT00049543 | COMPLETED | Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE3 |
| NCT01167244 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Bristol-Myers Squibb |
2010-08 | PHASE2 |
| NCT00095836 | COMPLETED | Head and Neck Cancer |
Massachusetts General Hospital |
2003-03 | PHASE2 |
| NCT00467077 | TERMINATED | Kidney Cancer |
California Cancer Consortium |
2004-09 | PHASE2 |
| NCT00452244 | COMPLETED | Lung Cancer |
National Cancer Center, Korea |
2006-05 | PHASE2 |
| NCT00770588 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) |
AstraZeneca |
2008-09 | PHASE4 |
| NCT00616499 | UNKNOWN | Lung Cancer |
Yonsei University |
2006-11 | PHASE2 |
| NCT00083057 | COMPLETED | Head and Neck Cancer |
National Institutes of Health Clinical Center (CC) |
2004-05 | PHASE1 |
| NCT01066195 | UNKNOWN | Non-small Cell Lung Cancer |
Samsung Medical Center |
2008-05 | PHASE3 |
| NCT00588445 | COMPLETED | Lung Cancer; Non-small Cell Lung Cancer; Bronchioloalveolar Cancer |
Memorial Sloan Kettering Cancer Center |
2004-06 | PHASE2 |
| NCT00553254 | COMPLETED | Carcinoma, Non Small Cell Lung |
Pfizer |
2008-02-05 | PHASE2 |
| NCT00096486 | COMPLETED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2004-05 | PHASE1; PHASE2 |
| NCT00033449 | TERMINATED | Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx |
National Cancer Institute (NCI) |
2002-02 | PHASE1 |
| NCT00614809 | UNKNOWN | Non-Small Cell Lung Cancer; Brain Metastasis |
Guangdong Provincial People's Hospital |
2007-12 | PHASE2 |
| NCT01040780 | COMPLETED | Non-small Cell Lung Cancer |
Betta Pharmaceuticals Co., Ltd. |
2009-02 | PHASE3 |
| NCT00042991 | COMPLETED | Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Oligodendroglioma |
National Cancer Institute (NCI) |
2002-07 | PHASE1; PHASE2 |
| NCT00483561 | TERMINATED | Prostate Cancer |
University of Nebraska |
2004-01 | PHASE2 |
| NCT00455936 | COMPLETED | Lung Cancer |
National Cancer Center, Korea |
2005-10 | PHASE3 |
| NCT00807066 | COMPLETED | Non Small Cell Lung Cancer |
Fondazione Humanitas per la Ricerca |
2008-11 | PHASE3 |
| NCT00522145 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Kadmon Corporation, LLC |
2007-05 | PHASE2 |
| NCT00681967 | COMPLETED | Head and Neck Cancer |
AstraZeneca |
2004-02 | PHASE1 |
| NCT00536107 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
AstraZeneca |
2007-10 | PHASE4 |
| NCT00409006 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2007-02 | PHASE2 |
| NCT00169221 | TERMINATED | Head and Neck Cancer |
Groupe Oncologie Radiotherapie Tete et Cou |
2005-09 | PHASE2 |
| NCT00088907 | TERMINATED | Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer |
National Cancer Institute (NCI) |
2004-08 | PHASE3 |
| NCT00238251 | COMPLETED | Lung Cancer; Metastatic Cancer |
Swiss Cancer Institute |
2005-05 | PHASE2 |
| NCT00497250 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Fudan University |
2007-07 | PHASE1 |
| NCT00608868 | COMPLETED | Non Small Cell Lung Carcinoma |
AstraZeneca |
2007-01 | PHASE4 |
| NCT00198380 | COMPLETED | Pneumonic-type Adenocarcinoma (P-ADC); Lung Adenocarcinoma With Bronchiolo-alveolar Feature |
Intergroupe Francophone de Cancerologie Thoracique |
2005-04 | PHASE2 |
| NCT00091156 | TERMINATED | Lung Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-05 | PHASE3 |
| NCT00198393 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Intergroupe Francophone de Cancerologie Thoracique |
2004-11 | PHASE2 |
| NCT00519077 | COMPLETED | Head and Neck Neoplasms |
University of Chicago |
2005-03 | PHASE2 |
| NCT00322452 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2006-03 | PHASE3 |
| NCT00290719 | TERMINATED | Esophageal Cancer |
University of California, San Francisco |
2005-11 | PHASE1 |
| NCT00085566 | COMPLETED | Brain and Central Nervous System Tumors; Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2004-03 | PHASE1; PHASE2 |
| NCT00423397 | UNKNOWN | Non-melanomatous Skin Cancer |
University of California, San Diego |
2006-09 | PHASE1; PHASE2 |
| NCT00068497 | COMPLETED | Anaplastic Thyroid Cancer; Insular Thyroid Cancer; Metastatic Parathyroid Cancer; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Parathyroid Cancer; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Thyroid Cancer; Recurrent Verrucous Carcinoma of the Larynx; Stage III Follicular Thyroid Cancer; Stage III Papillary Thyroid Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Larynx; Stage IIIB Non-small Cell Lung Cancer; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Non-small Cell Lung Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Basal Cell Carcinoma of the Lip; Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Follicular Thyroid Cancer; Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Lymphoepithelioma of the Oropharynx; Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Papillary Thyroid Cancer; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Basal Cell Carcinoma of the Lip; Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Follicular Thyroid Cancer; Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Lymphoepithelioma of the Oropharynx; Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Papillary Thyroid Cancer; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Basal Cell Carcinoma of the Lip; Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Follicular Thyroid Cancer; Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Lymphoepithelioma of the Oropharynx; Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Papillary Thyroid Cancer; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Thryoid Gland Nonmedullary Carcinoma; Thyroid Gland Medullary Carcinoma; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary |
National Cancer Institute (NCI) |
2003-08 | |
| NCT00344773 | COMPLETED | Pulmonary Cancer |
AstraZeneca |
2006-03 | PHASE2 |
| NCT00130702 | COMPLETED | Myelogenous Leukemia, Acute |
Dana-Farber Cancer Institute |
2005-08 | PHASE2 |
| NCT00049062 | COMPLETED | Breast Cancer |
The University of Texas Health Science Center at San Antonio |
2002-09 | PHASE2 |
| NCT00246974 | COMPLETED | Bladder Cancer |
AstraZeneca |
2003-05 | PHASE2 |
| NCT00113529 | COMPLETED | Carcinoma, Renal Cell |
Pfizer |
2004-10 | PHASE1; PHASE2 |
| NCT00206219 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
AstraZeneca |
2003-11 | PHASE3 |
| NCT00820417 | COMPLETED | Colorectal Cancer; Head and Neck Cancer; Non Small Cell Lung Cancer (NSCLC) |
Harrison Clinical Research |
2004-06 | PHASE1 |
| NCT00066378 | COMPLETED | Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2003-05 | PHASE2 |
| NCT00100945 | COMPLETED | Esophageal Cancer |
Alliance for Clinical Trials in Oncology |
2005-07 | PHASE2 |
| NCT00041106 | COMPLETED | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter |
National Cancer Institute (NCI) |
2002-05 | PHASE2 |
| NCT00024154 | COMPLETED | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2002-02 | PHASE2 |
| NCT00310154 | COMPLETED | Lung Cancer |
Wake Forest University Health Sciences |
2003-11 | PHASE1 |
| NCT00135135 | COMPLETED | Neuroblastoma |
St. Jude Children's Research Hospital |
2005-08 | PHASE2 |
| NCT00188617 | COMPLETED | LUNG CANCER |
University Health Network, Toronto |
2005-01 | PHASE2 |
| NCT00075439 | COMPLETED | Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma; WDHA Syndrome |
National Cancer Institute (NCI) |
2003-12 | PHASE2 |
| NCT00239343 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-10 | PHASE2 |
| NCT00039390 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2002-04 | PHASE1 |
| NCT00478049 | COMPLETED | NSCLC |
AstraZeneca |
2005-09 | PHASE3 |
| NCT00076388 | COMPLETED | Non-Small-Cell Lung Carcinoma |
AstraZeneca |
2004-02 | PHASE3 |
| NCT00212108 | COMPLETED | Nasopharyngeal Carcinoma |
National University Hospital, Singapore |
2003-11 | PHASE1; PHASE2 |
| NCT00020709 | COMPLETED | Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2001-06 | PHASE3 |
| NCT00259064 | COMPLETED | NSCLC |
AstraZeneca |
2004-09 | PHASE2; PHASE3 |
| NCT00411047 | COMPLETED | Lung Cancer |
Massachusetts General Hospital |
2005-09 | PHASE2 |
| NCT00229697 | COMPLETED | Breast Neoplasms |
AstraZeneca |
2003-10 | PHASE2 |
| NCT00026364 | COMPLETED | Colorectal Cancer |
National Cancer Institute (NCI) |
2001-11 | PHASE1 |
| NCT00258297 | TERMINATED | Esophageal Cancer |
University of Rochester |
2004-04 | PHASE2 |
| NCT00084708 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Roswell Park Cancer Institute |
2002-11 | PHASE1 |
| NCT00206414 | TERMINATED | BREAST CANCER |
Baylor Breast Care Center |
2003-01 | PHASE2 |
| NCT00062062 | COMPLETED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2004-10 | PHASE2 |
| NCT00025675 | COMPLETED | Brain and Central Nervous System Tumors |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2001-10-09 | PHASE2 |
| NCT00084786 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Memorial Sloan Kettering Cancer Center |
2004-03 | PHASE1 |
| NCT00093652 | TERMINATED | Esophageal Cancer |
Roswell Park Cancer Institute |
2003-05 | PHASE1; PHASE2 |
| NCT00162318 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Eli Lilly and Company |
2005-03 | PHASE1 |
| NCT00024089 | COMPLETED | Head and Neck Cancer |
National Cancer Institute (NCI) |
2001-07 | PHASE2 |
| NCT00040794 | COMPLETED | Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-05 | PHASE2 |
| NCT00025207 | COMPLETED | Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma |
National Cancer Institute (NCI) |
2001-09 | PHASE2 |
| NCT00193284 | COMPLETED | Head and Neck Cancer |
SCRI Development Innovations, LLC |
2003-10 | PHASE2 |
| NCT00233623 | WITHDRAWN | Metastatic Colorectal Cancer |
AstraZeneca |
2004-07 | PHASE2 |
| NCT00103051 | COMPLETED | Lung Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-12 | PHASE2 |
| NCT00087334 | TERMINATED | Colorectal Cancer |
Roswell Park Cancer Institute |
2004-01 | PHASE1; PHASE2 |
| NCT00052754 | COMPLETED | Sarcoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2002-10 | PHASE2 |
| NCT00091247 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Alliance for Clinical Trials in Oncology |
2004-12 | |
| NCT00052208 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma |
National Cancer Institute (NCI) |
2002-03 | PHASE1; PHASE2 |
| NCT00071994 | COMPLETED | Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer |
National Cancer Institute (NCI) |
2004-02 | PHASE2 |
| NCT00080743 | COMPLETED | Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2004-01 | PHASE2 |
| NCT00027625 | COMPLETED | Brain and Central Nervous System Tumors |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2002-01-28 | PHASE1 |
| NCT00029003 | COMPLETED | Bronchoalveolar Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2001-12 | PHASE2 |
| NCT00052585 | TERMINATED | Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage IV Colon Cancer; Stage IV Rectal Cancer |
National Cancer Institute (NCI) |
2002-10 | PHASE2 |
| NCT00040781 | COMPLETED | Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2002-06 | PHASE1 |
| NCT00217698 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2003-11 | PHASE2 |
| NCT00027690 | COMPLETED | Recurrent Uterine Corpus Carcinoma |
National Cancer Institute (NCI) |
2002-06 | PHASE2 |
| NCT00062270 | COMPLETED | Lung Cancer |
University of Alabama at Birmingham |
2003-05 | PHASE1; PHASE2 |
| NCT00082667 | TERMINATED | Breast Cancer |
Vanderbilt-Ingram Cancer Center |
2002-10 | PHASE2 |
| NCT00066339 | COMPLETED | Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2003-05 | PHASE2 |
| NCT00034879 | COMPLETED | Carcinoma; Non-small-cell Lung; Metastases; Neoplasm |
AstraZeneca |
2000-08 | PHASE3 |
| NCT00030524 | COMPLETED | Colorectal Cancer |
The University of Texas Health Science Center at San Antonio |
2002-01 | PHASE2 |
| NCT00014170 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma |
National Cancer Institute (NCI) |
2001-03 | PHASE2 |
| NCT00025116 | COMPLETED | Prostate Cancer |
NCIC Clinical Trials Group |
2001-04-24 | PHASE2 |
| NCT00014144 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer |
SWOG Cancer Research Network |
2001-02 | PHASE2 |
| NCT00014183 | COMPLETED | Kidney Cancer |
University of Maryland, Baltimore |
2001-01 | PHASE2 |
| NCT00005806 | COMPLETED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
1999-09 | PHASE1 |
| NCT00242788 | COMPLETED | Colorectal Cancer |
AstraZeneca |
2004-02 | PHASE1; PHASE2 |
| NCT00635856 | COMPLETED | Prostate Cancer |
AstraZeneca |
2001-05 | PHASE2 |
| NCT00635973 | COMPLETED | Cancer |
AstraZeneca |
2000-02 | PHASE3 |
| NCT00241475 | COMPLETED | Prostate Cancer |
AstraZeneca |
2003-12 | PHASE2 |
| NCT00177242 | COMPLETED | Cancer |
University of Pittsburgh |
2004-09 | PHASE2 |
| NCT00333294 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2004-09 | PHASE2 |
| NCT00098462 | WITHDRAWN | Lung Cancer |
Jonsson Comprehensive Cancer Center |
2004-10 | PHASE1; PHASE2 |
| NCT00298688 | COMPLETED | Small Cell Lung Cancer |
AstraZeneca |
2004-09 | PHASE2 |
| NCT00006049 | UNKNOWN | Lung Cancer |
AstraZeneca |
2000-05 | PHASE3 |
| NCT00016991 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
2001-06 | PHASE2 |
| NCT00012337 | COMPLETED | Kidney Cancer |
Memorial Sloan Kettering Cancer Center |
2001-01 | PHASE2 |
| NCT00256711 | COMPLETED | Non-Small-Cell Lung Carcinoma |
AstraZeneca |
2004-07 | PHASE2 |
| NCT00252707 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2003-09 | PHASE3 |
| NCT00238797 | COMPLETED | Glioblastoma |
AstraZeneca |
2003-02 | PHASE2 |
| NCT00080340 | COMPLETED | Non Small Cell Lung Carcinoma |
Telik |
PHASE3 | |
| NCT00268255 | WITHDRAWN | Non-small Cell Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
PHASE1; PHASE2 | |
| NCT00319618 | COMPLETED | Metastatic Breast Cancer |
AstraZeneca |
2003-06 | PHASE2 |
| NCT00025142 | COMPLETED | Colorectal Cancer |
Stanford University |
2001-07 | PHASE2 |
| NCT00239291 | COMPLETED | Non-Metastatic Prostate Cancer |
AstraZeneca |
2003-01 | PHASE1; PHASE2 |
| NCT00265070 | COMPLETED | Prostate Cancer |
AstraZeneca |
2003-01 | PHASE2 |
| NCT00234403 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-05 | PHASE2 |
| NCT00023699 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
2001-08 | PHASE2 |
| NCT01024712 | UNKNOWN | Lung Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2009-05 | PHASE2 |
| NCT00255489 | COMPLETED | Non-small-cell Lung Cancer |
AstraZeneca |
2004-05 | PHASE1 |
| NCT00632723 | COMPLETED | Breast Cancer |
AstraZeneca |
2001-04 | PHASE2 |
| NCT00234468 | TERMINATED | Non Small Cell Lung Carcinoma |
AstraZeneca |
2004-01 | PHASE3 |
| NCT00255463 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE2 |
| NCT00025350 | COMPLETED | Colorectal Cancer |
Eastern Cooperative Oncology Group |
2001-10 | PHASE2 |
| NCT00234442 | TERMINATED | Brain Neoplasms; Non Small Cell Lung Cancer |
AstraZeneca |
2004-07 | PHASE2 |
| NCT00319800 | UNKNOWN | Non-Small Cell Lung Cancer |
Gachon University Gil Medical Center |
2006-02 | PHASE2 |
| NCT00242749 | COMPLETED | Cancer of Head and Neck |
AstraZeneca |
2002-12 | PHASE2 |
| NCT00247481 | COMPLETED | Breast Cancer |
AstraZeneca |
2002-09 | PHASE2 |
| NCT00252811 | WITHDRAWN | Breast Cancer |
AstraZeneca |
2004-02 | PHASE2 |
| NCT00234416 | COMPLETED | Pancreatic Cancer |
AstraZeneca |
2002-08 | PHASE1; PHASE2 |
| NCT00264498 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
AstraZeneca |
2004-10 | PHASE2 |
| NCT00255476 | COMPLETED | Squamous Cell Cancer; Cancer of Head and Neck |
AstraZeneca |
2004-02 | PHASE2 |
| NCT00144066 | COMPLETED | Lung Cancer |
West Japan Thoracic Oncology Group |
2003-01 | PHASE3 |
| NCT00006048 | UNKNOWN | Lung Cancer |
AstraZeneca |
2000-05 | PHASE3 |
| NCT00242801 | COMPLETED | NSCLC |
AstraZeneca |
2003-07 | PHASE3 |
| NCT00049556 | COMPLETED | Cervical Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
National Cancer Institute (NCI) |
2002-10 | PHASE2 |
| NCT00237900 | TERMINATED | Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC |
AstraZeneca |
2003-07 | PHASE1; PHASE2 |
| NCT00233636 | WITHDRAWN | Head and Neck Cancer; Carcinoma, Squamous Cell |
AstraZeneca |
2003-07 | PHASE2 |
| NCT00955695 | UNKNOWN | Lung Cancer |
National Cancer Center, Korea |
2009-05 | PHASE3 |
| NCT00637026 | COMPLETED | Breast Cancer |
AstraZeneca |
2003-07 | PHASE2 |
| NCT00229723 | COMPLETED | Neoplasms, Squamous Cell |
AstraZeneca |
2004-11 | PHASE2 |
| NCT00127829 | COMPLETED | Tumors |
AstraZeneca |
2005-07 | PHASE1 |
| NCT00252798 | COMPLETED | Non Small Cell Lung Carcinoma |
AstraZeneca |
2002-07 | PHASE1 |
| NCT00239304 | COMPLETED | Head and Neck Neoplasms |
AstraZeneca |
2003-06 | PHASE1; PHASE2 |
| NCT00234429 | COMPLETED | Colorectal Cancer |
AstraZeneca |
2003-11 | PHASE2; PHASE3 |
| NCT00228488 | COMPLETED | Head and Neck Cancer |
AstraZeneca |
2004-06 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-03-09)
Check the
Gefitinib (ZD1839)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Gefitinib (ZD1839) Mechanism of Action: EGFR Inhibition in Non-Small Cell Lung Cancer Cells Research
- Gefitinib (ZD1839): Selectivity & Specificity
- Gefitinib (ZD1839) Working Concentration | Cell Culture | Treatment
- Gefitinib (ZD1839) Solubility in DMSO
- Gefitinib (ZD1839) Stock Solution
- Gefitinib (ZD1839) Storage
- Gefitinib (ZD1839) Stability
- Gefitinib (ZD1839) Combination Database
- Gefitinib (ZD1839) Molecular Weight
- Gefitinib (ZD1839) SMILES
- Gefitinib (ZD1839) CAS Number
- Gefitinib (ZD1839) Chemical Structure (2D and 3D)
- Gefitinib (ZD1839) IC50 for Cell-based and Cell-free Assays
- Gefitinib (ZD1839) Sigma (SML1657)? Try a better option.
- Gefitinib (ZD1839) MedChemExpress (HY-50895)? Try a better option.
- Gefitinib (ZD1839) APExBIO (A8219)? Try a better option.
- Gefitinib (ZD1839) Cayman (13166)? Try a better option.
- Gefitinib (ZD1839) Tocris (3000)? Try a better option.
- Gefitinib (ZD1839) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.